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158Discontinuation of preoperative clopidogrel is
unnecessary in peripheral arterial surgery
Carlos Saadeh, MD, FRCSC, FACS, and Julien Sfeir, MD, Byblos and Beirut, Lebanon
Objective: The optimal management of preoperative clopidogrel remains controversial, as vascular surgeons are increas-
ingly encountering patients treated with clopidogrel as part of dual antiplatelet therapy. Current practice differs
considerably, from cessation of the medication at least 5 days before surgery to proceeding with surgery without delay.
The purpose of this prospective, nonrandomized, comparative study was to determine the effect of preoperative exposure
to clopidogrel and aspirin on perioperative bleeding complications in patients undergoing open arterial surgery.
Methods: Data were collected prospectively on 647 consecutive major arterial procedures from 2005 through mid-2012.
Patients were classiﬁed into two groups: the clopidogrel group consisted of 305 procedures performed in 269 patients
who were maintained, after obtaining informed consent, on dual clopidogrel and aspirin up to the time of surgery and the
no-clopidogrel group consisted of 342 procedures completed in 298 patients who were taking neither medication
together or were taking aspirin alone. The primary composite end point was reoperation for bleeding and bleeding-related
death. Secondary end points included blood transfusion requirements, hematoma formation, the procedure duration, as
well as hospital and intensive care unit length of stay.
Results: The patients taking clopidogrel had a higher cardiovascular risk proﬁle and a higher prevalence of prior peripheral
and coronary stents (P < .0001). Clopidogrel use was common across all operation categories: 59% of carotid endar-
terectomy patients (104 of 177), 43% of lower extremity bypass patients (147 of 344), and 43% of abdominal aortic
bypass patients (54 of 126). The difference in the primary end point between the clopidogrel and no-clopidogrel groups
was not statistically signiﬁcant (0.65% and 0.3%, respectively; P [.55). No bleeding-related deaths were observed.
Further analysis revealed a similar incidence of stable hematomas. Blood transfusions were mainly required by patients
undergoing aortic surgery, at similar rates and volumes in the clopidogrel and no-clopidogrel groups: abdominal aortic
bypass cohort (a mean of 1.6 units packed red blood cells needed in 72% vs a mean of 1.6 units in 69%, respectively;
P [.76); lower extremity bypass cohort (a mean of 1.5 units needed in 15% vs 1.3 units needed in 11%; P < .004).
The mean operative time and intensive care unit and hospital lengths of stay were not longer in clopidogrel recipients.
Conclusions: Combined therapy with clopidogrel and aspirin up to the day of surgery is not associated with increased
bleeding complications or transfusion requirements. Data from this study do not validate the perceived higher risk of
perioperative bleeding in clopidogrel patients and do support the strategy of continued clopidogrel use in patients
undergoing peripheral arterial surgery. (J Vasc Surg 2013;58:1586-92.)Dual antiplatelet therapy (APT) with clopidogrel and
aspirin has become the standard of care to prevent throm-
botic complications in patients with acute coronary
syndrome and after cardiologic, neurovascular, and periph-
eral arterial stent placement.1-3 Indications for clopidogrel
use have further expanded to include polyvascular patients
presenting with symptomatic carotid4-7 and peripheral arte-
rial occlusive disease (PAOD)8-10 for secondary prevention
of stroke, myocardial infarction, and death. Clopidogrel
prescriptions are also expected to increase in clinical prac-
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6stents and the recent availability of generic clopidogrel.
All this makes it currently one of the most prescribed medi-
cations worldwide.11
Vascular surgeons are therefore constantly facing the
critical issue of perioperative clopidogrel safety in this more
prevalent group of patients.12,13 Although some surgeons
would proceed with arterial surgery assuming a higher-
than-usual risk of bleeding, others would postpone the
surgical intervention to minimize the risk of hemorrhage
or have their patients discontinue the medication 5 to 10
days preoperatively at a likely cost of more thrombotic
events.14
In sharp contrast to coronary artery bypass grafting
(CABG), where multiple studies have shown a signiﬁcantly
higher risk of postoperative bleeding and transfusion require-
ments in patients taking clopidogrel,15-19 few data have been
published on the effect of perioperative clopidogrel, in combi-
nation with aspirin or alone, in vascular surgery.20-26 Current
recommendations, which are based on small clinical series and
case reports, aremainly subjective and certainly not deﬁnitive,
thus explaining the large variations in the practice of vascular
specialists. The aim of this study was to assess whether expo-
sure to clopidogrel, in combination with low-dose aspirin,
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perioperative bleeding inpatients undergoingopenperipheral
arterial reconstructions.
METHODS
This study was approved by the respective Ethics
Committees of all four institutions involved.
Patients. All consecutive patients undergoing open
major arterial surgery, between January 2005 and June
2012, were enrolled into the study. Three types of operations
were retained: abdominal aortic bypass (AAB), lower ex-
tremity bypass (LEB), and carotid endarterectomy (CEA).
Not included were endovascular aneurysm repair and emer-
gency procedures for hemorrhage, namely, ruptured abdom-
inal aortic aneurysm (AAA) or arterial trauma. Patients were
excluded if they met any of the following criteria: combined
open and endovascular hybrid procedures, congenital or
acquired bleeding disorder identiﬁed preoperatively (von
Willebrand disease, hemophilia), simultaneous CEA and
CABG, preoperative blood transfusions for anemia, lost to
follow-up #30 days after surgery, or informed consent not
given.
After excluding 19 patients, including one patient lost
to follow-up, there were 567 eligible patients who under-
went 647 arterial procedures and were classiﬁed into two
groups. The clopidogrel group consisted of 305 procedures
performed in 269 patients who were taking Plavix
(75 mg/d; Sanoﬁ-Aventis, Bridgewater, NJ) and aspirin
(81 to 100 mg/d) before their scheduled operations and
were speciﬁcally asked to maintain their dual antiplatelet
medications up to the time of surgery. A written informed
consent form, explaining the potential risks of performing
the arterial procedure under clopidogrel, had to be signed
by the patient, a family member, or a designated represen-
tative. The no-clopidogrel group consisted of 342 proce-
dures performed in 298 patients who were receiving
neither medication together (20%) or were taking aspirin
alone (80%).
End points. Data on all patients, related to>60 demo-
graphic and clinical variables, were recorded and collected
prospectively. Outcome comparisons were assessed between
both arms and according to the type of vascular procedure.
The primary composite end point was reoperation for
bleeding and bleeding-related death. Secondary end points
included blood transfusion requirements within the index
hospitalization, hematoma formation, the duration of the
procedures, and hospital and intensive care unit (ICU)
lengths of stay.
Operative technique. All procedures were done by
a single vascular surgeon with the assistance of a junior
vascular surgeon and a physician assistant. Interventions in
patients who were taking clopidogrel were performed under
general anesthesia. AAB procedures included a combination
of aortoaortic bypass, aortobi-iliac bypass, and aortobife-
moral bypass for AAA or aortoiliac occlusive disease. For
LEB procedures, in situ saphenous vein grafts were used
for all infrapopliteal and below-knee femoropopliteal
bypass procedures, and reversed autogenous veinwas used in44.5% of above-knee femoropopliteal bypass procedures.
Polytetraﬂuoroethylene grafts were used for all crossover
femorofemoral bypass procedures and for 55.5% of above-
knee femoropopliteal bypass procedures. All CEA proce-
dures were completed under routine shunting through an
arteriotomy on the anterior surface of the distal common
carotid artery and proximal internal carotid artery, whichwas
closed with a collagen-coated dacron Hemagard patch
(Maquet, Wayne, NJ). All CEA patients were sent to the
ICU for a closer monitoring of blood pressure.
Several intraoperative details areworthmentioning: only
35-50 U/kg of systemic heparin is initiated before cross-
clamping, and if clamping time exceeds 90 minutes, another
similar dose is administered. Protamine for heparin reversal
and suction drains are not used. Dissection is limited to
obtain only the needed exposure: vein preparation or har-
vesting for LEB is achieved through multiple mini-
incisions. BioGlue, a topical biologic sealant (CryoLife Inc,
Kennesaw, Ga) is used at all anastomotic sites where pros-
thetic grafts are used as bypass material. Surgicel, oxidized
cellulose (Ethicon, Somerville, NJ), is used in CEA on the
suture line of the patch angioplasty. Vigorous control of
blood pressure is maintained at all times in the perioperative
period by anesthesiologists. Closure of the incisions is under-
taken only after ensuring the ﬁeld is completely dry.
Deﬁnitions. Severe bleeding requiring reoperation
was deﬁned as hemodynamic compromise, expanding
hematoma, persistent blood oozing from the wound,
decrease in hemoglobin of >5 g/dL or 15% reduction in
hematocrit, and neck swelling with respiratory distress or
swallowing compromise. Nonoperative hematoma was
deﬁned as nonexpanding blood collection, documented
by ultrasound imaging or computed tomography scan,
stable in size on serial clinical examination or ultrasound
imaging or computed tomography scan, and not causing
organ compromise. Neck hematoma was considered
different from tissue swelling or simple ecchymosis, both
of which are common after CEA. Transfusion requirements
were deﬁned as transfusions administered at the time of
surgery or within the index hospitalization.
Blood management. Estimated blood loss is obtained
through collaboration between anesthesiologists, surgeons,
and nurses but was not included in the secondary end points
because blood loss is often difﬁcult to estimatewith accuracy.
Blood transfusions were guided by patient-related factors,
such as advanced age and comorbidities (ie, cardiac and renal
dysfunction), and the patient’s hemodynamic status and
clinical condition. Intraoperatively, the decision to begin
a transfusion of red blood cells (RBCs) was considered if
blood loss was active or expected and the starting hematocrit
was<30%. In the postoperative period, indications to initiate
transfusion were mainly based on hemoglobin levels
of <10 g/dL.
Vasodilator-stimulated phosphoprotein assay. In
the late stages of the study, 40 clopidogrel patients were
assessed with the vasodilator-stimulated phosphoprotein
(VASP) phosphorylation assay to determine patients at
increased risk of bleeding. A platelet reactivity index of<55%
Table I. Patient demographics and comorbidities in the
clopidogrel and no-clopidogrel groups
Variablea Clopidogrel No clopidogrel P
Procedures, total 305 342
Patients, total 269 298 .764
Male sex 197 (73.2) 228 (76.5) .666
Male-to-female ratio 2.7 3.2 .666
Age, years 69 6 8.6 68 6 9.7 .896
Risk factors
Hypertension 269 (88.1) 274 (80) .036
Smoking (current) 195 (63.9) 215 (62.8) .790
Dyslipidemia 241 (79) 219 (64) .001
Diabetes mellitus 173 (56.7) 145 (42.3) .003
CAD
Prior MI 99 (32) 52 (15) .017
PCI/stenting 143 (46.8) 27 (7.9) <.001
Drug-eluting stent 39 (27) 0 <.001
CABG 44 (14.4) 55 (16) .568
Prior stroke 32 (10.5) 15 (4.3) .452
Peripheral stenting 30 (9.8) 11 (3.2) .008
RI (Cr >1.8 mg/dL) 28 (9.1) 29 (8.5) .780
Hemodialysis 5 (1.6) 6 (1.7) .903
COPD 55 (18) 67 (19.6) .620
Platelets, /mm3 256 6 61 254 6 68 .995
Medications
Aspirin 305 (100) 274 (80) <.001
Statins 226 (74) 163 (47.6) <.001
b-blockers 238 (78) 241 (70.5) <.001
COPD, Chronic obstructive pulmonary disease; CABG, coronary artery
bypass graft; CAD, coronary artery disease; Cr, creatinine; MI, myocardial
infarction; PCI, percutaneous coronary intervention; RI, renal insufﬁciency.
aCategoric variables are shown as number (%) and continuous variables are
presented as mean 6 standard deviation.
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to clopidogrel, whereas a platelet reactivity index of $55%
means decreased platelet inhibition by clopidogrel and
a poor response. Five patients were excluded from this
subgroup for potential drug interactions with concomitant
omeprazole and calcium-channel blockers.Of the remaining
35 patients, 27 were found to be good responders and eight
low responders to clopidogrel.
Statistical analysis. All values for continuous variables
are expressed as mean 6 standard deviation, and categoric
variables are presented as corresponding frequencies and
percentages. The Student t-test (two-tailed) was used to
test the differences between means and between propor-
tions. The Levene F test was used to verify the homoge-
neity of variances. P values were always computed, and
a difference was considered statistically signiﬁcant when
P < .05. Statistical analysis was performed using SPSS 17
software (SPSS Inc, Chicago, Ill).
RESULTS
The baseline demographic characteristics of the
patients (Table I) were similar between the two groups.
Clopidogrel was used by 47% of all patients, and its intake
was common across all operation categories: 58.7% of CEA
patients (104 of 177), 42.7% of LEB patients (147 of 344),
and 42.8% of AAB patients (54 of 126). As expected,
patients receiving dual APT had a higher cardiovascular
(CV) risk proﬁle with a greater prevalence of dyslipidemia,
diabetes mellitus, hypertension, and myocardial infarction
than those in the no-clopidogrel group, as well as a signiﬁ-
cantly higher prevalence of prior coronary stents, peripheral
stents, lower extremity surgical revascularization, and statin
intake. The main indications for adding clopidogrel to
aspirin were prior coronary artery stenting, followed by
advanced PAOD in patients at high risk of CV events
and symptomatic carotid disease.
There was no statistically signiﬁcant difference in the
primary composite end point between the clopidogrel and
no-clopidogrel groups. No bleeding-related deaths were
observed.Overall, the re-exploration rate because of postop-
erative bleeding was similar between the two arms (0.65%
and 0.3%, respectively; P ¼.55). Three reoperations were
required: oneCEA patient and one LEB patient in the clopi-
dogrel group and one LEB patient in the no-clopidogrel
group. At re-exploration, bleeding was found arising from
the superﬁcial tissue layers in the clopidogrel patients and
from the wound edges in the no-clopidogrel patient. When
the 305 procedures performed under dual clopidogrel and
aspirin therapy were compared with the 274 completed
under aspirin alone in the no-clopidogrel group, reoperation
for bleeding was similar, at 0.65% (2 of 305) vs 0.36% (1 of
274), respectively (P ¼.50). In patients assessed with the
VASP assay, results between good and low responders to clo-
pidogrel were similar (0% in each group).
Secondary end points, analyzed by type of procedure,
were also similar between the two groups. For the AAB
cohort, outcome data are reported in Table II, A-C, whichincludes a separate subgroup analysis of the patients diag-
nosed with AAA and for those with aortoiliac occlusive
disease. Blood transfusions were mainly required by patients
undergoing aortic surgery, at similar rates and volumes in the
two groups: 72% of patients in the clopidogrel group needed
a mean of 1.6 units of packed RBCs (PRBCs), whereas 69%
of patients in the no-clopidogrel group needed amean of 1.6
units of PRBCs. Outcomes remained essentially the same in
the two subgroups, except for higher estimated blood loss
among clopidogrel patients in the AAA subgroup. Platelet
transfusions were not used.
For the CEA and LEB cohorts, secondary outcomes
are reported in Tables III and IV. In LEB surgery, expo-
sure to blood transfusions was limited (15% vs 11%), with
more PRBC units needed in clopidogrel patients (1.5 vs
1.36 units), largely due to a higher rate of distal in situ
vein bypass surgeries with longer incisions. In the CEA
cohort, one stable neck hematoma was diagnosed and
managed conservatively (1 of 104 [1%] clopidogrel vs
0% no-clopidogrel), whereas leg hematomas were equally
noted in the LEB cohort (3 of 147 [2%] clopidogrel vs 2
of 196 [1%] no-clopidogrel). Outcome data revealed
equivalent 30-day mortality and morbidity rates in all
cohorts. In addition, the median intraoperative time for
each type of procedure and the mean ICU and hospital
lengths of stay were not longer in clopidogrel recipients.
Table II. Secondary end points and clinical outcome for
aortic procedures
A, Analysis of all 126 abdominal aortic bypass procedures
Variablea
Clopidogrel No clopidogrel
P(n ¼ 54) (n ¼ 72)
Clinical indication: AAA 35 (65) 49 (68) .800
All-cause mortality 0 0 1
Transfusion requirements
Incidence 39 (72) 50 (69) .764
PRBCs, units 1.6 6 0.7 1.6 6 0.6 1
Hematoma 0 0 1
Operative time, minutes 122 6 28 123 6 28 .994
Blood loss, mL 910 6 150 790 6 170 .025
Length of stay, days
ICU 1.1 6 0.8 1.3 6 0.6 .021
Hospital 6.3 6 1.6 6.2 6 1.8 .851
B, Analysis of 84 abdominal aortic bypass procedures performed for
AAA
Variablea
Clopidogrel No clopidogrel
P(n ¼ 35) (n ¼ 49)
Transfusion requirements
Incidence 27 (77) 37 (75) .879
PRBCs, units 1.7 6 0.5 1.7 6 0.3 1
Operative time, minutes 118 6 22 120 6 26 .617
Blood loss, mL 1360 6 110 1210 6 130 .001
Hospital stay, days 6.1 6 0.9 6.5 6 1.7 .208
C, Analysis of 42 abdominal aortic bypass procedures performed for
aortoiliac occlusive disease
Variablea
Clopidogrel No clopidogrel
P(n ¼ 19) (n ¼ 23)
Transfusion requirements
Incidence 12 (63) 13 (56) .735
PRBCs, mean units 1.2 6 0.8 1.3 6 0.4 .602
Operative time, minutes 131 6 36 128 6 32 .777
Blood loss, mL 490 6 90 455 6 70 .164
Hospital stay, days 6.6 6 2.4 5.8 6 1.5 .195
AAA, Abdominal aortic aneurysm; ICU, intensive care unit; PRBCs, packed
red blood cells.
aCategoric variables are shown as number (%) and continuous variables are
presented as mean 6 standard deviation.
Table III. Secondary end points and clinical outcome
for 177 carotid endarterectomy (CEA) procedures
Variablea
Clopidogrel No clopidogrel
P(n ¼ 104) (n ¼ 73)
Symptomatic stenosis 63 (61) 26 (36) .015
Stroke or death 0 0 1
Hematoma 1 (1) 0 .792
Operative time, minutes 69 6 11 65 6 9 .804
Hospital stay, days 2.8 6 0.8 2.7 6 0.6 .213
aCategoric variables are shown as number (%) and continuous variables are
presented as mean 6 standard deviation.
Table IV. Secondary end points and clinical outcome for
344 lower extremity bypass (LEB) procedures
Variablesa
Clopidogrel No clopidogrel
P(n ¼ 147) (n ¼ 197)
Critical limb ischemia 129 (88) 158 (80) .188
All-cause mortality 0 1 (0.5) .554
Transfusion requirements
Incidence 22 (15) 22 (11) .334
PRBCs, units 1.5 6 0.6 1.3 6 0.8 .004
Hematoma 3 (2) 2 (1) .468
Operative time, minutes 88 6 33 79 6 27 .925
Blood loss, mL 210 6 130 190 6 110 .989
Hospital stay, days 4.7 6 1.9 4.5 6 2.3 .688
PRBCs, Packed red blood cells.
aCategoric variables are shown as number (%) and continuous variables are
presented as mean 6 standard deviation.
JOURNAL OF VASCULAR SURGERY
Volume 58, Number 6 Saadeh and Sfeir 1589DISCUSSION
The most important ﬁnding of this prospective compar-
ative study is that perioperative clopidogrel, in combination
with aspirin, is not associated with greater bleeding compli-
cations across all categories of major arterial surgery. This
will undisputedly have potential implications on the optimal
management of these patients, which is still controversial
>15 years after the advent of clopidogrel.27 In fact, vascular
surgeons are regularly confronted with complex decisions
concerning the cessation or continuation of clopidogrel
because an increasing number of vascular patients are on
dual APT for longer periods than expected. Accordingly,
the most recent American College of Cardiology Founda-
tion/American Heart Association guidelines on PAODintroduced a new recommendation stating that dual APT
with clopidogrel and aspirin may be considered in patients
at high CV risk presenting with “symptomatic athero-
sclerotic lower extremity PAOD including those with inter-
mittent claudication or critical limb ischemia, prior LE
revascularization (endovascular or surgical), or prior
amputation.”28
In view of the paucity of evidence-based guidelines on
the appropriate use of perioperative clopidogrel, there
appears to be a clear lack of consensus among vascular
specialists on this issue. A 2009 survey of 399 European
surgeons found that 43% and 55%, respectively, would
stop clopidogrel before CEA for symptomatic and asymp-
tomatic patients.12 The type of vascular procedure may
also inﬂuence the operator’s decision: some surgeons would
favor clopidogrel discontinuation in aortoiliac reconstruc-
tions, citing a major hemostatic challenge, whereas others
would do the same in distal lower extremity revasculariza-
tions because of more extensive incisions.
The perceived higher risk of bleeding in vascular patients
taking clopidogrel is most likely an extrapolation from
the outcomes of similar patients undergoing CABG
surgery.15-19 Although not all, the overwhelming majority
of the studies identiﬁed clopidogrel exposure #5 days of
cardiac surgery as the strongest predictor of reoperation for
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threefold more likely to require re-exploration than patients
not receiving clopidogrel. On the basis of the current
data, including the 2012 American College of Cardiology
Foundation/American Heart Association guideline update,
it is still recommended that clopidogrel be withheld, if clinical
conditions allow, for at least 5 days before planned CABG.29
In addition to the potent and irreversible inhibition of platelet
function by clopidogrel, cardiac surgery involves the frequent
use of cardiopulmonary bypass with full intraoperative hepa-
rinization and hypothermia. Subsequent transfusion require-
ments, usually related to cardiopulmonary bypass-ampliﬁed
platelet dysfunction, prolongedbleeding times, and dilutional
thrombocytopenia, are therefore expected to be greater in
patients prescribed clopidogrel. By contrast, similar condi-
tions associated with major blood loss are less prevalent
in peripheral arterial surgery, except for complex aortic
reconstructions.
Very few studies of clopidogrel administration up to
the day of operation have been published in vascular
surgery, and their small size, conﬂicting results, and lack
of statistical power preclude reliable conclusions from
being drawn. In patients undergoing CEA, Fleming
et al21 reported no difference in bleeding complications
between 19 clopidogrel-treated patients and 81 untreated
patients. Likewise, Chechik et al22 reported similar postop-
erative complications in 26 CEA patients on uninterrupted
clopidogrel compared with 81 nonclopidogrel patients.
Among 27 patients who required reoperation for postoper-
ative neck bleeding, Payne et al23 showed no association
with any particular preoperative APT intake, only a signiﬁ-
cantly higher prevalence of postoperative hypertension. In
42 patients receiving clopidogrel up to 5 days before
CEA, Wait et al24 found a small but signiﬁcant increase
in nonoperative neck swelling. In contrast, Rosenbaum
et al25 found that clopidogrel use resulted in a signiﬁcant
risk of developing a neck hematoma, mainly with the
Dacron patch repair, when comparing 50 patients taking
clopidogrel with 171 patients taking acetylsalicylic acid.25
Baracchini et al26 reported a re-exploration rate of 4.7%
after eversion CEA and identiﬁed postoperative hyperten-
sion and clopidogrel as predictors of neck bleeding: of their
69 patients who required reoperation for bleeding, 44 had
severe hypertension in the recovery room. This observation
was conﬁrmed by several authors, who documented higher
hypertension rates of up to 24% after eversion CEA
compared with 6% after conventional CEA.30,31 In the
present study, the different outcomes might be related to
a tighter control of hypertension or to some operative
details such as underheparinization and the porosity of
the patch.
In a review of 1246 patients taking clopidogrel #48
hours of surgery, recorded from 15 institutions in the
Vascular Registry of New England, Stone et al20 found
that clopidogrel was not associated with major bleeding
complications across a spectrum of peripheral arterial oper-
ations, although complementary data, such as hematoma
formation and surgical drain use, were not reported.Our study, by comparison, differs in many aspects.
Endovascular aneurysm repair was not included because
it represents a minimally invasive procedure. All patients
in the clopidogrel group were left on dual clopidogrel
and aspirin therapy until the time of surgery, not #48
hours of the operation, which might have had a more
severe effect on platelet dysfunction. Forty-seven percent
of our patients were receiving clopidogrel (compared
with 11.9% in the New England registry), a percentage
that may seem excessive but reﬂects today’s “real-world”
vascular practice in speciﬁc patient populations at high
risk for CV ischemic events. In concordance with our ﬁnd-
ings, growing rates of clopidogrel use in vascular patients
are being reported: 30.8% of CEA patients in the Barac-
chini et al26 study and 46% of CEA patients in a recent
report on the results of isolated CEA vs combined CEA/
CABG.32 Even the New England Vascular Registry may
have had a higher percentage of clopidogrel use, because
the authors state in the discussion of their article, “we are
unable to comment on the number of patients who may
have had prior clopidogrel withheld prior to surgery.”20
The ﬁndings of this study provide vascular surgeons with
clear-cut answers to lingering concerns about the safety of
dual APT. To the best of our knowledge, the aortic group
(AAB), comprising 54 patients operated on under dual
APT, is the largest reported in the literature, with results
similar to the 72 no-clopidogrel patients of the same group,
in terms of mortality, morbidity, reoperation for hemor-
rhage, and transfusion requirements. Moreover, no platelet
transfusions were needed. Caution, however, must be exer-
cised in patients undergoing CEA due to the closed space of
dissection and the proximity of vital neurorespiratory struc-
tures that could be readily compromised if major bleeding
were to occur. Utmost care is also required in complex cases
of infrapopliteal bypass, where diffuse bleeding may lead to
delayed blood loss.
In an attempt to guide therapy by determining the
effect of clopidogrel responsiveness on results, we ran the
VASP assay preoperatively, currently the most speciﬁc
P2Y12 receptor test for monitoring of platelet function,
on our last 40 patients taking clopidogrel. After adjustment
for potential drug interactions,33,34 23% of these patients
were documented to have a poor response to clopidogrel,
a rate consistent with previous cardiology trials.35 Although
no signiﬁcant difference was found in the respective end
points between responders and nonresponders, the small
sample size of the subgroup leads to a restrictive interpre-
tation of such data and requires further investigations.
In sum, our study is among the few that provide insight
into contemporary patterns of clopidogrel use, effect of the
interindividual variability of clopidogrel responsiveness, and
comparative outcome events recorded prospectively in
the setting of major arterial surgery. Just as previous bleeding
concerns associated with aspirin were overcome with
increased operator experience, bleeding risks with
clopidogrel are minimized with growing familiarity of such
situations supplemented by a few reﬁnements in operative
technique, including systemic underheparinization, vigorous
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hemostatic agents, and meticulous attention to hemostasis.
Finally, the present study has some limitations that
deserve mention. First, it is not a randomized controlled
trial. However, considering that patients with recent acute
coronary syndrome or drug-eluting stent deployment
cannot be randomized for being at high risk of stent
thrombosis and cardiac events if clopidogrel were to be
prematurely discontinued, such a trial could only be under-
taken in selected patients. Furthermore, it might be argued
that without blinding the physicians, some of the secondary
end points could be biased by the prior knowledge of the
patients’ APT regimen. However, we attempted to mini-
mize the opportunity for bias by ensuring the data were
analyzed by an independent analyst who had no involve-
ment in the outcome of the trial and by having postopera-
tive care protocols strictly applied to all patients.
The second limitation consists of some unavoidable
inherent sources of bias, given the extremely low incidence
of major bleeding complications. However, we concluded
from a post hoc power analysis that our study, with a sample
size of 647 patients, was powered enough to show signiﬁcant
differences for theLEBandCEAcohorts, with a potential for
a type II error in the smaller AAB subgroups. Nevertheless,
larger prospective studies are warranted to conﬁrm our
ﬁndings.
Although the studywasmulticentered, involving univer-
sity and community hospitals, the third limitation is that the
same surgeon performed all procedures. In this regard, the
standardized approach we used in preoperative assessment,
anesthesiology, and surgical technique may have helped
reduce a number of potential variables associated with
hemorrhage.
CONCLUSIONS
Our growing experience, based on a large sample of
vascular patients, shows that dual APT with clopidogrel
and low-dose aspirin up to the day of surgery is not associ-
ated with increased mortality, reoperation for bleeding,
transfusion requirements, or hematoma formation, com-
pared with patients taking aspirin alone or without APT.
Data from this study do not validate the perceived higher
risk of perioperative bleeding in clopidogrel patients and
do support the strategy of continued clopidogrel use,
unless speciﬁcally contraindicated, in patients undergoing
peripheral arterial surgery.
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